This New Medicare Pilot Program Offers GLP-1s For $50 A Month. Here’s What You Need To Know
Medicare has launched a new pilot program called Bridge that allows eligible beneficiaries to access GLP-1 obesity drugs from Novo Nordisk and Eli Lilly for $50 per month, a dramatic reduction from hundreds of dollars. However, the program faces implementation challenges and is only guaranteed through the end of 2027, creating uncertainty for patients starting long-term therapies.
Summary
Starting this week, millions of eligible Medicare patients gain access to GLP-1 obesity drugs through a new federal pilot program called Bridge, marking a significant shift in Medicare policy. Traditionally, Medicare has barred coverage of medications prescribed solely for obesity, but this program creates a temporary pathway for coverage. Eligible beneficiaries must meet certain requirements, including a BMI over 35 and the presence of certain obesity-related conditions, and can access these medications for a $50 monthly copay instead of the typical hundreds of dollars per month. This move could potentially reach as many as 20 million new patients according to Novo Nordisk and Eli Lilly's estimates, with officials expecting several million beneficiaries to enroll immediately. The program addresses a significant access gap for older Americans who have been unable to afford these popular weight loss drugs. However, the rollout faces practical challenges. Doctors must submit prior authorization requests to confirm patient eligibility before coverage is approved, and physicians are concerned that an influx of new patients could strain already busy clinics and pharmacies. More critically, the coverage is not permanent—unless the Trump administration extends or replaces the program, Bridge coverage is scheduled to expire by the end of 2027, and any permanent changes would require congressional approval. This creates a significant risk for patients who will begin long-term obesity therapies without knowing whether coverage will continue beyond 2027.
Key Insights
- GLP-1 obesity drugs have cost hundreds of dollars per month, making them out of reach for most older Americans on Medicare until this week's program launch
- The Bridge program represents a major shift because Medicare has traditionally barred coverage of medications prescribed solely for obesity
- Novo Nordisk and Eli Lilly estimate the program could reach as many as 20 million eligible patients, with several million expected to enroll immediately
- Physicians warn that a wave of new patients could put additional pressure on already busy clinics and pharmacies over the next couple of months
- The coverage through Bridge is scheduled to expire by the end of 2027 unless the Trump administration extends it, and permanent changes would require congressional approval
Topics
Transcript
[0:00] Popular weight loss drugs have remained out of reach for most older Americans in Medicare for years. That's because GLP-1s can cost hundreds of dollars per month, but that changes this week. Starting Wednesday, millions of eligible Medicare patients can access GLP-1 obesity drugs >> [music] >> from Novo Nordisk and Eli Lilly for a copay of just $50 per month. It's a major shift for a federal program that has traditionally barred coverage of medications prescribed solely for obesity. So, what happened? Well, there's a new Medicare pilot program called Bridge that's creating a temporary pathway for coverage. Patients [0:31] who meet [music] certain requirements, including those with a BMI of over 35 and people with certain obesity-related…
Full transcript available for MurmurCast members
Sign Up to AccessMore from CNBC
How Trump Could Benefit From A Possible ICE Contract
President Trump purchased $1-5 million in Axon Enterprise stock in February 2026, and two weeks later ICE announced a $220 million contract request to quadruple its taser inventory from the company Trump invested in. While the White House claims no conflict of interest and states Trump's trades are managed independently, the timing has drawn scrutiny from ethics experts and government watchdogs.
Inside The Rise And Fall Of Kohl's
Kohl's, once a retail darling, experienced a dramatic decline from an $82 stock peak in 2018 to under $20, primarily due to loss of brand identity and customer focus. New CEO Michael Bender has implemented a turnaround strategy focused on returning to core values, resulting in recent positive performance metrics and a 120% stock jump over the past year.
Why Analysts Say The Auto Industry Is Heading For Demographic Cliff
The US auto industry faces a structural decline driven by slowing population growth, changing consumer behavior, and technological disruption. New car sales could fall from record levels to 13.7-15.7 million units by 2040 due to fewer young people getting licenses, unaffordable vehicle prices, and longer vehicle lifespans.
How The AI Data Center Buildout Is Creating Boom For The Gas Turbine Industry
AI data centers operated by hyperscalers like Amazon, Google, and Meta are driving explosive demand for natural gas turbines, with GE Vernova leading production at its South Carolina facility. Turbine prices have surged 300% in three years, and the company now books orders extending to 2030-2031, though environmental concerns about this technology are mounting.
How The U.S. Box Office Is Having Its Strongest Year Since 2019
The 2026 summer box office is experiencing its strongest performance since 2019, with $1.8 billion already earned and tracking nearly 2% below pre-pandemic levels. A diverse mix of sequels and original films, including musicals, dramedies, and horror films, is driving attendance, positioning the year for potentially the first $10 billion domestic box office since 2019.